Cardiology · Rheumatology · 2 h ago
Colchicine Not Linked to Lower Cardiovascular Risk in Chinese Cohort
A cohort study of 285,466 Chinese adults without prior cardiovascular disease who initiated urate-lowering therapy found no association between colchicine use and incident cardiovascular events. Colchicine users had lower all-cause mortality, but the observational findings do not establish a causal effect.
- No association with incident cardiovascular disease was observed.
- CVD incidence was 1.62 versus 1.59 per 100 person-years.
- Colchicine users had lower observed all-cause mortality.
- Observational results do not establish causality.
Researchers used Beijing employee medical claims data from 2008–2017 to assess cardiovascular outcomes among adults without prior cardiovascular disease who initiated urate-lowering therapy. Colchicine exposure was defined as at least one dispensing within 30 days of treatment initiation. After propensity-score weighting, the analysis included 6,157 colchicine users and 279,309 non-users, followed for a median of 3.05 years. The primary outcome was incident cardiovascular disease; ischemic heart disease, heart failure, cerebrovascular disease, stroke and all-cause mortality were also assessed.
Weighted cardiovascular disease incidence was 1.62 per 100 person-years among colchicine users and 1.59 among non-users (hazard ratio [HR], 1.01; 95% CI, 0.91–1.12). No significant associations were found for ischemic heart disease, heart failure, cerebrovascular disease or stroke. All-cause mortality was lower among colchicine users (HR, 0.74; 95% CI, 0.64–0.86).
The findings do not support routine colchicine use for primary cardiovascular prevention when urate-lowering therapy is started. Because this was an observational study using administrative claims, residual confounding may remain; the lower mortality association does not establish that colchicine caused the difference.
In practice
For adults without prior cardiovascular disease who are starting urate-lowering therapy, this large Chinese claims-based cohort found no association between colchicine dispensing near treatment initiation and subsequent cardiovascular events over a median 3.05 years. The results do not support routine colchicine use for primary cardiovascular prevention in this setting. This was an observational study, so residual confounding is possible; the lower observed all-cause mortality among users cannot be interpreted as a treatment effect.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
BMC Medicine: Colchicine use and cardiovascular event risk in Chinese adults starting urate-lowering therapy: a cohort study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.